Epigenomics AG (Frankfurt Prime Standard: ECX, OTCQX: EPGNY), the German-American cancer molecular diagnostics company, and BioChain, an early cancer diagnostic company with operations in both USA and China and Epigenomics’ exclusive strategic commercialization partner in China, today announced that testing based on the proprietary Septin9 biomarker was included in the Chinese Guideline on Screening, Endoscopic Diagnosis and Treatment of Early Colorectal Cancer (CRC).
{iframe}http://www.epigenomics.com/news-investors/news-media/pressemitteilungen/article/epigenomics-und-biochain-geben-die-aufnahme-ihres-unternehmenseigenen-septin9-basierten-bluttests-in.html{/iframe}